Stay updated on Pembrolizumab After Weekly Paclitaxel Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab After Weekly Paclitaxel Clinical Trial page.

Latest updates to the Pembrolizumab After Weekly Paclitaxel Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedPage revision updated from v3.2.0 to v3.3.2.SummaryDifference0.1%

- Check28 days agoChange DetectedThe funding/operational status notice was removed from the page; trial details and study information remain unchanged.SummaryDifference0.4%

- Check42 days agoChange DetectedNo significant content changes were detected; the page still presents the study overview, eligibility criteria, design, and outcome measures.SummaryDifference0.5%

- Check71 days agoChange DetectedSignificant update: new operating-status notice and version bump to v3.2.0; previous v3.1.0 tag removed. Core content impacted by the new status information.SummaryDifference4%

- Check78 days agoChange DetectedUpdate to v3.1.0 with removal of the Ovarian cancer resource from GARD and removal of v3.0.2; overall, a small scope/content shift and new release note rather than substantive page content changes.SummaryDifference0.5%

- Check92 days agoChange DetectedVersion updated from v3.0.1 to v3.0.2; the 'Back to Top' control was removed.SummaryDifference0.2%

Stay in the know with updates to Pembrolizumab After Weekly Paclitaxel Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab After Weekly Paclitaxel Clinical Trial page.